Elisabeth Rexen Ulven

Elisabeth Rexen Ulven

Associate Professor

ORCID: 0000-0003-1243-7587

Publication year:
All
1 - 7 out of 7Page size: 10
  1. 2013

  2. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469

    Urban, C., Hamacher, A., Partke, H. J., Roden, M., Schinner, S., Ulven, Elisabeth Rexen, Due-Hansen, M. E., Ulven, Trond, Gohlke, H. & Kassack, M. U., 17 Jul 2013, In: Naunyn-Schmiedeberg's Archives of Pharmacology. 386, 12, p. 1021-2030 1010 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor

    Hudson, B. D., Due-Hansen, M. E., Ulven, Elisabeth Rexen, Hansen, A., Mackenzie, A. E., Murdoch, H., Pandey, S. K., Ward, R. J., Marquez, R., Tikhonova, I. G., Ulven, Trond & Milligan, G., 14 Jun 2013, In: Journal of Biological Chemistry. 288, p. 17296-17312 17 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Discovery of TUG-770

    Ulven, Elisabeth Rexen, Hansen, S. V. F., Urban, C., Hudson, B. D., Wargent, E. T., Grundmann, M., Jenkins, L., Zaibi, M., Stocker, C. J., Ullrich, S., Kostenis, E., Kassack, M. U., Milligan, G., Cawthorne, M. A. & Ulven, Trond, 9 May 2013, In: A C S Medicinal Chemistry Letters. 4, 5, p. 441-445 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability

    Ulven, Elisabeth Rexen, Due-Hansen, M. E., Urban, C., Grundmann, M., Schmidt, J., Hansen, S. V. F., Hudson, B. D., Zaibi, M., Markussen, S. B., Hagesaether, E., Milligan, G., Cawthorne, M. A., Kostenis, E., Kassack, M. U. & Ulven, Trond, 14 Feb 2013, In: Journal of Medicinal Chemistry. 56, 3, p. 982-992 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Reevaluation of Fatty acid receptor 1 (FFAR1/GPR40) as drug target for the stimulation of insulin secretion in humans

    Wagner, R., Kaiser, G., Gerst, F., Ulven, Elisabeth Rexen, Due-Hansen, M. E., Grundmann, M., Machicao, F., Peter, A., Kostenis, E., Ulven, Trond, Fritsche, A., Häring, H. & Ullrich, S., 1 Feb 2013, In: Diabetes. 62, 6, p. 2106-2111 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Mucus can change the permeation rank order of drug candidates

    Hagesaether, E., Ulven, Elisabeth Rexen, Due-Hansen, M. E. & Ulven, Trond, 2013, In: International Journal of Pharmaceutics. 452, 1-2, p. 276-282 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism

    Hudson, B. D., Shimpukade, B., Mackenzie, A. E., Butcher, A. J., Pediani, J. D., Ulven, Elisabeth Rexen, Heathcote, H., Tobin, A. B., Ulven, Trond & Milligan, G., 2013, In: Molecular Pharmacology. 84, 5, p. 710-725 16 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 201719978